AcelRx Pharmaceuticals Inc expected to post a loss of 7 cents a share - Earnings Preview

Talphera

01/11/2021 23:00

* AcelRx Pharmaceuticals Inc  ACRX.OQ   ACRX.O  is expected
to show a rise in quarterly revenue when it reports  results on
November 3 (estimated). 
* The Hayward, California-based company is expected to report  a
38.9% increase in revenue to $1.9 million from $1.37 million a
year ago, according to the mean estimate from 2 analysts, based
on Refinitiv data. 
​* Refinitiv's mean analyst estimate for AcelRx Pharmaceuticals
Inc is for a loss of 7 cents per share. For the same quarter
last year, the company reported a loss of 10 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for AcelRx
Pharmaceuticals Inc is $5​, about 82.7% above​ its last closing
price of $0.87. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Jun. 302021   -0.08       -0.08      -0.08     Met     -4.3
 Mar. 312021   -0.08       -0.08      -0.08     Met     4
 Dec. 312020   -0.12       -0.10      -0.10     Met     3.2​
 Sep. 302020   -0.08       -0.08      -0.10     Missed  -21.2
 ​​Jun.        -0.12       -0.14      -0.08     Beat    41.8
 302020                                                 
 Mar. 312020   -0.17       -0.17      -0.20     Missed  -17.6​
 Dec. 312019               -0.20      -0.18     Beat    8.5
 Sep. 302019   -0.21       -0.22      -0.16     Beat    28.1
 This summary was machine generated November 1 at 23:00 GMT.  All
figures in US dollars unless otherwise stated